Opaleye Management as of Sept. 30, 2020
Portfolio Holdings for Opaleye Management
Opaleye Management holds 55 positions in its portfolio as reported in the September 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Ocular Therapeutix (OCUL) | 8.9 | $46M | 6.0M | 7.61 | |
| Protara Therapeutics Com Stk (TARA) | 8.4 | $43M | 2.6M | 16.83 | |
| Eton Pharmaceuticals (ETON) | 5.6 | $29M | 3.6M | 7.90 | |
| Cardiff Oncology (CRDF) | 4.8 | $25M | 1.7M | 14.19 | |
| Acutus Medical (AFIB) | 4.4 | $22M | 750k | 29.80 | |
| Chemocentryx | 3.8 | $20M | 356k | 54.80 | |
| Neoleukin Therapeutics | 3.3 | $17M | 1.4M | 12.00 | |
| Harrow Health (HROW) | 3.2 | $17M | 3.0M | 5.59 | |
| Codexis (CDXS) | 3.2 | $16M | 1.4M | 11.74 | |
| Eidos Therapeutics | 3.1 | $16M | 316k | 50.53 | |
| Vaxcyte (PCVX) | 3.0 | $16M | 313k | 49.38 | |
| Celldex Therapeutics Com New (CLDX) | 2.9 | $15M | 992k | 14.83 | |
| Macrogenics (MGNX) | 2.6 | $13M | 527k | 25.19 | |
| Deciphera Pharmaceuticals (DCPH) | 2.2 | $11M | 222k | 51.30 | |
| Stereotaxis Com New (STXS) | 2.1 | $11M | 3.0M | 3.58 | |
| Aptose Biosciences Com New | 2.1 | $11M | 1.8M | 6.00 | |
| Avenue Therapeutics Com New | 2.1 | $11M | 985k | 10.83 | |
| Tg Therapeutics (TGTX) | 2.0 | $10M | 390k | 26.76 | |
| Tracon Pharmaceuticals Com New (TCON) | 2.0 | $10M | 2.0M | 5.17 | |
| Fortress Biotech | 2.0 | $10M | 3.8M | 2.68 | |
| Myovant Sciences | 1.9 | $9.6M | 683k | 14.05 | |
| Chimerix (CMRX) | 1.9 | $9.6M | 3.8M | 2.49 | |
| Seres Therapeutics (MCRB) | 1.9 | $9.5M | 335k | 28.31 | |
| Axovant Gene The | 1.8 | $9.4M | 2.0M | 4.62 | |
| Kiniksa Pharmaceuticals Com Cl A (KNSA) | 1.7 | $8.8M | 338k | 25.97 | |
| Xoma Corp Del Com New (XOMA) | 1.7 | $8.6M | 455k | 18.84 | |
| Cerecor | 1.5 | $7.7M | 3.4M | 2.28 | |
| Biohaven Pharmaceutical Holding | 1.5 | $7.4M | 114k | 65.01 | |
| Adamas Pharmaceuticals | 1.2 | $6.1M | 1.5M | 4.12 | |
| Fibrogen (FGEN) | 1.2 | $6.0M | 147k | 41.12 | |
| Tela Bio (TELA) | 1.2 | $6.0M | 362k | 16.54 | |
| Kalvista Pharmaceuticals (KALV) | 1.1 | $5.9M | 470k | 12.47 | |
| Mei Pharma Com New | 0.9 | $4.9M | 1.6M | 3.12 | |
| Edap Tms Sa Sponsored Adr (EDAP) | 0.9 | $4.8M | 1.0M | 4.60 | |
| Cytokinetics Com New (CYTK) | 0.9 | $4.5M | 209k | 21.65 | |
| Crinetics Pharmaceuticals In (CRNX) | 0.7 | $3.8M | 240k | 15.67 | |
| Fulcrum Therapeutics (FULC) | 0.7 | $3.6M | 452k | 7.93 | |
| Lumos Pharma (LUMO) | 0.7 | $3.3M | 241k | 13.82 | |
| Kezar Life Sciences (KZR) | 0.6 | $3.3M | 678k | 4.84 | |
| Verastem | 0.6 | $3.2M | 2.2M | 1.46 | |
| Cidara Therapeutics Inc Common Stock Usd 0.0001 (CDTX) | 0.5 | $2.8M | 971k | 2.85 | |
| Aeglea Biotherapeutics | 0.5 | $2.7M | 375k | 7.09 | |
| Minerva Neurosciences | 0.5 | $2.4M | 767k | 3.18 | |
| Outset Med (OM) | 0.4 | $2.3M | 45k | 50.00 | |
| Essa Pharma Com New (EPIX) | 0.4 | $1.9M | 271k | 6.90 | |
| Sutro Biopharma (STRO) | 0.3 | $1.5M | 146k | 10.05 | |
| Contrafect Com New | 0.2 | $1.2M | 226k | 5.28 | |
| Concert Pharmaceuticals I equity | 0.2 | $982k | 100k | 9.82 | |
| Amarin Corp Sponsored Adr New (AMRN) | 0.2 | $947k | 225k | 4.21 | |
| X4 Pharmaceuticals (XFOR) | 0.1 | $508k | 75k | 6.77 | |
| Oncternal Therapeutics | 0.1 | $331k | 195k | 1.70 | |
| Pieris Pharmaceuticals (PIRS) | 0.1 | $300k | 145k | 2.07 | |
| Infinity Pharmaceuticals (INFIQ) | 0.0 | $137k | 3.2M | 0.04 | |
| Biolinerx Sponsored Ads (BLRX) | 0.0 | $33k | 17k | 1.98 | |
| Merus N V (MRUS) | 0.0 | $2.0k | 200.00 | 10.00 |
